CervoMed Inc. (NASDAQ:CRVO – Get Free Report) CEO John Alam purchased 100,000 shares of CervoMed stock in a transaction on Wednesday, November 18th. The stock was bought at an average price of $1.53 per share, with a total value of $153,000.00. Following the transaction, the chief executive officer owned 1,584,078 shares of the company’s stock, valued at approximately $2,423,639.34. This represents a 6.74% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
CervoMed Stock Up 9.8%
NASDAQ CRVO opened at $1.46 on Friday. CervoMed Inc. has a 52 week low of $1.27 and a 52 week high of $10.00. The stock’s 50-day moving average price is $2.24 and its 200-day moving average price is $3.20.
CervoMed (NASDAQ:CRVO – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. On average, research analysts anticipate that CervoMed Inc. will post -2.04 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Roth Capital set a $7.00 target price on shares of CervoMed in a research note on Thursday, August 20th. HC Wainwright reaffirmed a “buy” rating on shares of CervoMed in a report on Monday, October 5th. Chardan Capital upgraded CervoMed to a “strong-buy” rating in a research report on Monday, August 3rd. Wall Street Zen raised CervoMed from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings lowered CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, CervoMed currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.
Get Our Latest Stock Report on CRVO
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new position in CervoMed in the first quarter worth about $252,000. BlackRock Inc. purchased a new stake in CervoMed during the second quarter valued at approximately $167,000. Byrne Asset Management LLC raised its position in CervoMed by 248.6% during the second quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock valued at $159,000 after purchasing an additional 36,550 shares during the period. Citizens Financial Group Inc. RI purchased a new stake in CervoMed during the second quarter valued at approximately $116,000. Finally, Caprock Group LLC purchased a new stake in CervoMed during the third quarter valued at approximately $34,000. Institutional investors own 25.15% of the company’s stock.
CervoMed Company Profile
CervoMed is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on therapies intended to address underlying disease processes rather than only manage symptoms. The company’s lead drug candidate, neflamapimod, is an oral, brain-penetrant small molecule designed to inhibit p38 alpha mitogen-activated protein kinase. CervoMed has studied the candidate for dementia with Lewy bodies, a progressive neurodegenerative disorder. CervoMed was formed in 2023 when EIP Pharma combined with Diffusion Pharmaceuticals, which subsequently adopted the CervoMed name.
Featured Articles
- Five stocks we like better than CervoMed
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
